Journal Articles
Gottschalk LA, Falloon IRH, Marder SR, Lebell MB, Gift TE, Wynne LC. The prediction of relapse of schizophrenic patients using emotional data obtained from their relatives. Psychiatry Res, 25:261-276, 1988.
Marder SR, Van Putten T. Who should receive clozapine? Arch Gen Psychiatry, 45:865-867, 1988. Abstracted in Psychiatry Digest, 9:27-28, 1989.
Marder SR, Asarnow RF, Van Putten T. Information processing and maintenance dose requirements in schizophrenia. Psychopharmacol Bull, 24:247-250, 1988.
Asarnow RF, Marder SR, Mintz J, Van Putten T, Zimmerman KE. Differential effect of low and conventional doses of fluphenazine on schizophrenic outpatients with good or poor information processing abilities. Arch Gen Psychiatry, 45:822-826, 1988.
Gelenberg AJ, Van Putten T, Lavori PW, Wojik JD, Falk WE, Marder SR, Galvin-Nadeau M, Spring B, Mohs RC, Brotman AW. Anticholoinergic effects on memory: Benztropine versus amantadine. Journal of Clinical Psychiatry, 9:180-185, 1989.
Van Putten T, Marder SR, Mintz J, Poland RE: Haloperidol plasma levels and clinical response: a therapeutic window relationship. Psychopharm Bull 24:173-175, 1988.
Marder SR, Hubbard JW, Van Putten T, Midha KK. The pharmacokinetics of long-acting injectable neuroleptic drugs: Clinical implications. Psychopharmacology, 98:433-439, 1989.
Marder SR, Van Putten T, Aravagiri M, Hubbard JW, Hawes EM, McKay G, Midha KK. Plasma levels of parent drug and metabolites in patients receiving oral and depot fluphenazine. Psychopharm Bull, 25:479-482, 1989.
Van Putten T, Marder SR, Aravagiri M, Chabert N, Mintz J. Plasma homovanillic acid as a predictor of response to fluphenazine treatment. Psychopharm Bull, 1:89-91, 1989.
Irwin M, Van Putten T, Guze B, Marder SR. Pharmacolgic treatment of veterans with postraumatic stress disorder and concomitant affective disorder. Annals of Clinical Psychiatry 1:127-130, 1989.
Aravagiri M, Marder SR, Van Putten T. Determination of plasma homovanillic acid by column liquid chromatography with electrochemical detection. J Chromatog (Biomed-Applications), 525:419-425, 1990.
Aravagiri M, Marder SR, Van Putten T, Hawes EM, McKay G, Hubbard JW, Midha KK. Therapeutic monitoring of steady-state plasma levels of the N4-oxide metabolite of fluphenazine in chronically treated schizophrenic patients determined by a specific and sensitive radioimmunoassay. Therapeutic Drug Monitoring, 12:268-276, 1990.
Marder SR, Wirshing W, Van Putten T. Drug treatment of schizophrenia: Overview of Recent Research. Schizophrenia Research, 4:81-90, 1991.
Sullivan G, Marder SR, Liberman RP, Donahoe CP, Mintz J. Social skills and relapse history in outpatient schizophrenics. Psychiatry, 53:340-345, 1990.
Van Putten T, Marder SR, Mintz J. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry, 47:754-758, 1990.
Marder SR, Van Putten T, Aravagiri M, Hawes EM, Hubbard JW, McKay G, Mintz J, Midha KK. Fluphenazine plasma levels and clinical response. Psychopharm Bull, 26:256-259, 1990.
Bartzokis G, Garber HJ, Marder SR, Oldendorf WH. MRI in tardive dyskinesia: Shortened left caudate T2. Biological Psychiatry, 28:1027-1036, 1990.
Gorelick DA, Irwin MR, Schmidt-Lackner S, Marder SR. Alcoholism among male schizophrenic inpatients. Annals of Clinical Psychiatry 2:19-22, 1990.
Marder SR, Midha KK, Van Putten T, Aravagiri M, Hawes EM, Hubbard JW, McKay G, Mintz J. Plasma levels of fluphenazine in patients receiving fluphenazine decanoate: Relationship to clinical response. British Journal of Psychiatry, 158:658-665, 1991
Granholm E, Asarnow RF, Marder SR. Controlled information processing and the development of automatic detection responses in schizophrenia. Journal of Abnormal Psychology, 100:22-30, 1991.
Marder SR, Mintz J, Van Putten T, Lebell M, Wirshing WC, Johnson-Cronk K, Early prediction of relapse in schizophrenia: An application of Receiver Operating Characteristic (ROC) methods. Psychopharm Bull, 27:79-82, 1991.
Van Putten T, Marder SR, Wirshing WC, Aravagiri M, Chabert N. Neuroleptic plasma levels. Schizophrenia Bulletin, 17:197-216, 1991.
Van Putten T, Aravagiri M, Marder SR, Wirshing WC, Mintz J, Chabert N. Plasma fluphenazine levels and clinical response in newly admitted schizophrenic patients. Psychopharm Bull, 27:91-96, 1991.
Bartzokis G, Garber HJ, Griswold VJ, Oldendorf WH, Mintz J, Marder SR. T2 Hyperintense Foci on Magnetic Resonance Images of schizophrenic patients and controls. Psychiatry Research, 40:239-245, 1991.
Van Putten T, Marder SR, Mintz J. Serum prolactin as a correlate of clinical response to haloperidol. J Clin Psychopharmacol, 11:357-361, 1991.
Eckman TA, Wirshing WC, Marder SR, Liberman RP, Johnston-Cronk K, Zimmerman K, Mintz J. Technology for training schizophrenics in illness self-management: A controlled trial. Am J Psychiatry, 149:1549-1555, 1992.
Segal SP, Cohen D, Marder SR. Neuroleptic medications and prescription practices with sheltered-care residents: A 12-year perspective. Am J Public Health, 82:846-852, 1992
Van Putten T, Marder SR, Mintz J, Poland RE. Haloperidol plasma levels and clinical response: A therapeutic window relationship. Am J Psychiatry 149:500-505, 1992.
Glaser WM, Friedhoff LT, Marder SR, Brown WA. The determination of the steady-state pharmacokinetic profile of fluphenazine decanoate by gas chromatography/mass spectrometry detection. Schizophrenia Research, 8:111-117, 1992.
Lebell MB, Marder SR, Mintz J, Mintz LI, Tompson M, Wirshing WC, Johnstom-Cronk K, McKenzie J. Patients perception of family emotional climate and outcome in schizophrenia. Brit J Psychiatry 162:751-754, 1993.
Granholm E, Bartzokis G, Asarnow RF, Marder SR. Preliminary associations between motor procedural learning, basal ganglia T2 relaxation times, and tardive dyskinesia in schizophrenia. Psychiatry Research 1993;50:33-44.
Bartzokis G, Aravagiri M, Oldendorf WH, Mintz J, Marder SR. Field dependent transverse relaxation rate increase may be a specific measure of tissue iron stores. Magnetic Resonance in Medicine 29:459-464, 1993.
Aravagiri M, Marder SR, Van Putten T, Midha KK. Determination of Risperidone in Plasma by High-Performance Liquid Chromatography with Electrochemical Detection: Application to Therapeutic Drug Monitoring in Schizophrenic Patients. Journal of Pharmaceutical Sciences 82:447-449, 1993.
Marder SR, Wirshing WC, Van Putten T, Mintz J, McKenzie J, Johnson-Cronk K, Lebell M, Liberman RP. Fluphenazine versus placebo supplementation for prodromal signs of relapse in schizophrenia. Arch Gen Psychiatry 51:280-287, 1994.
Kane JM, Marder SR. Psychopharmacologic treatment of schizophrenia. Schizophr Bull 19:287-302, 1993.
Davis JM, Kane JM, Marder SR, Brauzer B, Gierl B, Schooler N, Casey DE, Hassan M. Dose response of prophylactic antipsychotics. J Clin Psychiatry 54,Suppl:24-30, 1993.
Wirshing WC, Marder SR, Eckman T, Liberman RP, Mintz J. Acquisition and retention of skills training methods in chronic schizophrenic outpatients. Psychopharmacol Bull 28:241-245, 1992.
Midha KK, Marder SR, Jaworski TJ, McKay G, Hubbard JW, Hawes EM, Van Putten T, Wirshing WC, Aravagiri M. Clinical perspectives of some neuroleptics through development and application of their assays. Therapeutic Drug Monitoring 15:179-189, 1993.
Liberman RP, Van Putten T, Marshall, BD, Mintz J, Bowen L, Kuehnel TG, Aravagiri M, Marder SR. Optimal drug and behavior therapy for treatment refractory schizophrenic patients. Am J Psychiatry, 1994;151: 756-759
Van Putten T, Marshall, BD, Liberman RP, Mintz J, Kuehnel TG, Bowen L, Aravagiri M, Marder SR. Systematic dosage reduction in treatment-resistant schizophrenic patients. Psychopharmacol Bull 29:315-320, 1993.
Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry, 151:825-835, 1994.
Hubbard JW, Midha KK, Hawes EM, McKay G, Marder SR, Aravagiri M, Korchinski ED. Metabolism of phenothiazine and butyrophenone antipsychotic drugs: A review of some recent research findings and clinical implications. Brit J Psychiatry 163(suppl. 22):19-24, 1993.
Aravagiri M, Marder SR, Van Putten T, Hawes EM, McKay G, Midha KK. Radioimmunoassay for 7-Hydroxy metabolite of fluphenazine and its application to plasma level monitoring in schizophrenic patients treated long term with oral and depot fluphenazine. Therapeutic Drug Monitoring 16:21-29, 1994.
Aravagiri M, Marder SR, Van Putten T, Marshall BD. Simultaneous determination of plasma haloperidol and its metabolite reduced haloperidol by liquid chromatography with electrochemical detection: plasma levels in schizophrenic patients treated with oral or intramuscular depot haloperidol. Journal of Chromatography B: Biomedical Applications1994;656:373-381.
Bartzokis G, Sultzer D, Mintz J, Holt LE, Marx P, Phelan CK, Marder SR. In vivo evaluation of brain iron in Alzherimer's Disease and normal subjects using MRI. Biol Psychiatry 1994;35:480-487.
Marder SR. The role of dosage and plasma level in neuroleptic relapse prevention. Acta Psychiatr Scand 1994;89(suppl 382):25-27.
Bartzokis G, Mintz J, Sultzer D, Marx P, Herzberg JS, Phelan CK, Marder SR. In vivo MR evaluation of age-related increases in brain iron. Am J Neuroradiol 1994;15:1129-1138.
Bartzokis G, Mintz J, Marx P, Osborn D, Gutkind D, Chiang F, Phelan C K, Marder S R. Reliability of in vivo volume measures of hippocampus and other brain structures using MRI. Magn Reson Imaging 1993; 11: 993-1006.
Midha KK, Hubbard JW, Marder SR, Marshall BD, Van Putten T, Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia. J Psychiatr Neurosci 1994;19:254-264.
Granholm E, Asarnow RF, Marder SR. Dual-task performance operating characteristics, resource limitations, and automatic processing in schizophrenia. Neuropsychology, 1996;10:11-21.
Granholm E, Asarnow RF, Marder SR. Display visual angle and attentional scanpaths on the span of apprehension task in schizophrenia. J Abn Psychology 1996;105:17-24.
Pahl JJ, Mazziotta JC, Bartzokis G, Cummings J, Altschuler L, Mintz J, Marder SR, Phelps M. Positron-Emission tomography in tardive dyskinesia. J Neuropsychiatry 1995; 4:457-465.
Aravagiri M, Marder SR, Yuwiler A, Midha KK, Kula NS, Baldessarini RJ. Distribution of fluphenazine and its metabolites in brain regions and other tissues of the rat. Neuropsychopharmacology 1995; 3:235-247.
Tompson MC, Goldstein MJ, Lebell MB, Mintz LI, Marder SR, Mintz J. Schizophrenic patients' perception of their relatives' attitudes. Psychiatry Research 1995;57:155-167.
Marder SR, Wirshing WC, Mintz J, McKenzie J, Johnson K, Eckman T, Lebell M, Zimmerman KZ, Liberman RP. Behavioral skills training versus group psychotherapy for outpatients with schizophrenia: Two-year outcome. Am J Psychiatry 1996;153:1585-1592.
Bartzokis G, Nuechterlein KH, Marder SR, Mintz J, Dery K, Laack K. Age at illness onset and left temporal lobe length in males with schizophrenia. Psychiatry Research 1996;67:189-201.
Marder SR. Management of treatment-resistant patients with schizophrenia. J Clin Psychiatry 1996;57(suppl 11):26-30.
Marder SR. Clinical experience with risperidone. [Review] J Clin Psychiatry 1996;57(suppl 9):57-61.
Aravagiri M, Ames D, Wirshing WC, Marder SR. Plasma level monitoring of olanzapine in patients with schizophrenia: Determination by High-Performance Liquid Chromatography with Electrochemical Detection. Therapeutic Drug Monitoring 1997;19:307-313.
Green MF, Marshall BD Jr., Wirshing WC, Ames D, Marder SR, McGurk S, Kern RS, Mintz J. Does risperidone improve verbal working memory in treatment-resistant schizophrenia?. Am J Psychiatry 1997;154:799-804.
Bartzokis G, Beckson M, Hance DB, Marx P, Foster JA, Marder SR. MR evaluation of age-related increase of brain iron in young adult and older normal males. Magnetic Resonance Imaging. 1997;15:29-35.
Ames D, Wirshing WC, Baker RW, Umbricht DS, Sun AB, Carter J, Schooler NR, Kane JM, Marder SR. Predictive value of eosinophilia for neutropenia during clozapine treatment. Journal of Clinical Psychiatry. 1996;57:579-81.
Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American Trials. Journal of Clinical Psychiatry. 1997;58:538-546.
Book Chapters
Marder SR, Van Putten T, Aravagiri M. Plasma level monitoring for maintenance neuroleptic therapy. in Dahl SG, Grove LF (eds) Clinical Pharmacology in Psychiatry: From Molecular Studies to Clinical Reality, Heidelberg: Springer-Verlag, pp 269-279, 1989.
Van Putten T, Marder SR, Mintz J, Poland RE. Haloperidol plasma levels and clinical respose: A therapeutic window relationship. Schulz SC, Tamminga CA (eds) Schizophrenia: Scientific Progress New York: Oxford, 325-332, 1989.
Pahl JJ, Bartzokis G, Maziotta JC, Cummings JL, Altshuler, LL, Marder SR, Phelps, ME. Positron emission tomography (PET) in schizophrenia research, in Die Schizophrenien -- Biologische und Familien -- Dynamische Konzepte zur Pathogenese (1980-1987), WP Kaschka, L Joraschky, M Langershausen (eds) Springer-Verlag, Heidelberg, 1988.
Van Putten T, Marder SR, Chabert N. The neuroleptic dysphoria syndrome. Williams R, Dalby JT (eds) Depression in Schizophrenics Plenum, 233-243, 1989.
Marder SR, Johnston-Cronk K, Wirshing WC, Eckman T. Schizophrenia and behavioral skills training. Beitman BD, Klerman GL (eds) Integrating Pharmacotherapy and Psychotherapy Washington, D.C.: American Psychiatric Press, 311-328, 1991.
Van Putten T, Marder SR, Wirshing W, Midha KK. Neuroleptic plasma levels in treatment-resistant schizophrenic patients. Angrist B, Schulz SC (eds) The Neuroleptic Nonresponsive Patient: Characterization and Treatment Washington, D.C.: American Psychiatric Press, 67-85, 1990.
Marder SR, Van Putten T, Aravagiri M, Hawes EM, Hubbard JW, McKay G, Mintz J, Midha KK. Therapeutic plasma levels of depot neuroleptics. Stefanis CN, Rabavilas AD, Soldatos CR (eds) Psychiatry: A World Perspective Volume 3 Amsterdam: Excerpta Medica, 111-116, 1990
Lebell MB, Marder SR, Mintz J, McKenzie J. Predicting schizophrenic relapse by a speech sample of family emotional climate. Stefanis CN, Rabavilas AD, Soldatos CR (eds) Psychiatry: A World Perspective Volume 3 Amsterdam: Excerpta Medica, 802-807, 1990
Midha KK, Jaworski TJ, Hawes EM, McKay G, Hubbard JW, Aravagiri M, Marder SR. Radioimmunoassay and other methods for trace analysis of N-oxide compounds. Hlavica P, Damani LA (eds) N-oxidation of Drugs. Biochemistry, Pharmacology, Toxicology. London: Chapman and Hall, 37-55, 1991.
Marder SR. Predictors of risk of relapse in schizophrenia. Kissling W (ed) Guidelines For Neuroleptic Relapse Prevention in Schizophrenia. Berlin:Springer-Verlag, 67-75, 1991.
Marder SR. Pharmacological treatment of schizophrenia. Kavanagh DJ (ed) Schizophrenia: An Overview and Practical Handbook. London: Chapman & Hall, 325-338, 1992.
Wirshing WC, Marder SR, Van Putten T. Future directions in antipsychotic drug treatment. Dunner DL (ed) Current Psychiatric Therapy. Philadelphia: WB Saunders, 544-551, 1992.
van Kammen DP, Marder SR. Dopamine Blocking Agents. to appear in H. Kaplan, B. Sadock (eds) Comprehensive Textbook of Psychiatry VI. Baltimore: Williams and Wilkins, 1987-2022, 1995.
van Kammen DP, Marder SR. Clozapine. to appear in H. Kaplan, B. Sadock (eds) Comprehensive Textbook of Psychiatry VI. Baltimore: Williams and Wilkins, 1979-1987, 1995.
Marder SR. Psychiatric Rating Scales. in H. Kaplan, B. Sadock (eds) Comprehensive Textbook of Psychiatry VI. Baltimore: Williams and Wilkins, 619-637, 1995.
Wirshing WC, Ames D, Marder SR, Hicks-Gray T. Schizophrenia. in M. Hersen, RT Ammerman, LA Sisson (eds) Handbook of Aggressive and Destructive Behavior New York: Plenum, 197-214, 1994.
Marder SR. Strategien zur Verbesserung des Verlaufes der chronischen Schizophrenie. H. Hinterhuber, F. Kulhanek, W.W. Fleischhacker, R. Neumann (eds) Pradiktoren und Therpieresistenz in der Psychiatrie Wiesbaden:Vieweg, 172-182, 1993.
Marder SR. Schizophrenia. RR Rakel (ed) Conn's Current Therapy Philadelphia: W.B. Saunders, 1122-1126, 1994
Kane JM, Schooler NR, Marder SR, Simpson GM, Casey DE. Methods for clinical evaluation of pharmacologic treatments of schizophrenia. RF Prien, DS Robinson (eds) Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines New York: Raven Press, 345-372, 1994.
Marder SR. Pharmacokinetic aspects of neuroleptics and prediction of outcome. W. Gaebel, AG Awad (Eds) Prediction of Neuroleptic Treatment Outcome in Schizophrenia: Concepts and Methods Vienna:Springer -Verlag, 71-78, 1994.
Wirshing WC, Marder SR, Van Putten T, Ames D. Acute treatment of schizophrenia.. FE Bloom, DJ Kupfer (Eds) Psychopharmacology: The Fourth Generation of Progress New York: Raven Press, 1259-1267, 1995.
Marder SR, Van Putten T. Antipsychotic Medications. AF Schatzberg, CB Nemeroff (Eds) The American Psychiatric Press Textbook of Psychopharmacology Washington DC: American Psychiatric Press, 435-456, 1995.
Van Putten T, Marder SR. Clinical use of neuroleptic plasma levels. CL Shriqui, HA Nasrallah (Eds) Contemporary Issues in the Treatment of Schizophrenia Washington DC: American Psychiatric Press, 247-261, 1995.
Ames D, Marder SR, Wirshing WC. The long-term treatment of schizophrenic disorders. RJ Ancill, MH Lader (Eds) Pharmacological Management of Chronic Psychiatric Disorders London: Bailliere Tindall, 511-532, 1995.
Ames D, Marder SR, Wirshing WC, Van Putten T. Ongoing research in the treatment of schizophrenia. JM Kane, H.-J. M ller, F Awouters (Eds) Serotonin in Antipsychotic Treatment: Mechanisms and Clinical Practice New York: Marcel Dekker, 13-30, 1996.
Ames D, Marder SR, Wirshing WC. Risperidone: Clinical Applications. A. Breier (Ed) The New Pharmacotherapy of Schizophrenia Washington DC: American Psychiatric Press, 15-40, 1996.
Marder SR. Antipsychotic Drugs A. Tasman, J. Kay, JA Lieberman (Ed) Psychiatry Philadelphia: WB Saunders, 1569-1586, 1996.
Marder SR, Wirshing WC, Ames D. Overview of antipsychotic medications.
DL Dunner (Ed) Current Psychiatric Therapy II Philadelphia: WB Saunders, 211-216, 1997.
Marder SR, Wirshing WC, Ames D. New antipsychotic drugs DL Dunner, JF Rosenbaum (Eds)
Annual of Drug Therapy Philadelphia: WB Saunders, 195-207, 1997
